Panacea Biotec Ltd
PANACEABIO
Price Chart
Scorecard
Performance
LowHasn't faired well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
HighStrong financials and growth story over the years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 0.57 | 0.82 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 32.79 | 3.97 | 0.98% |
Forecast & RatingsDetailed Forecast
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Panacea Biotec Limited is a health management company. The Company's principal business activity is the manufacture of allopathic pharmaceuticals preparations.
PeersCompare with peers
Biocon Ltd
Hester Biosciences Ltd
Zenotech Laboratories Ltd
Vivo Bio Tech Ltd
Transgene Biotek Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Financial TrendFinancial statements
Holdings TrendDetailed holdings
Low Pledged Promoter HoldingLower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
Mutual Fund HoldingIncreasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has almost stayed constant
Recent NewsAll news
Johnson & Johnson’s dengue antiviral drug shows positive results
5 days ago•Business Standard
Panacea Biotec Standalone December 2022 Net Sales at Rs 71.97 crore, up 87.03% Y-o-Y
4 weeks ago•Moneycontrol
Panacea Biotec reports consolidated net profit of Rs 19.37 crore in the December 2022 quarter
1 month ago•Business Standard
Recent EventsAll events
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Panacea Biotec Limited has informed the Exchange about the details of shares dematerialised during the month of February, 2023 under SEBI (Depositories and Participants) Regulations, 2018 | Download
Panacea Biotec Limited has informed the Exchange about the details of shares dematerialised during the month of February, 2023 under SEBI (Depositories and Participants) Regulations, 2018 | Download
Cash Dividend
Final • Div/Share: ₹ 0.75
Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant